Cynata Therapeutics Limited Stock Price To Earnings To Growth
| CYYNF Stock | USD 0.19 0.00 0.00% |
Cynata Therapeutics Limited fundamentals help investors to digest information that contributes to Cynata Therapeutics' financial success or failures. It also enables traders to predict the movement of Cynata Pink Sheet. The fundamental analysis module provides a way to measure Cynata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cynata Therapeutics pink sheet.
Cynata |
Cynata Therapeutics Limited Company Price To Earnings To Growth Analysis
Cynata Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Cynata Therapeutics Limited has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Cynata Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 143.28 M | |||
| Shares Owned By Insiders | 14.77 % | |||
| Shares Owned By Institutions | 24.80 % | |||
| Price To Book | 2.66 X | |||
| Price To Sales | 5.53 X | |||
| Revenue | 7.77 M | |||
| Gross Profit | 7.77 M | |||
| EBITDA | (13.56 M) | |||
| Net Income | (5.45 M) | |||
| Cash And Equivalents | 26.79 M | |||
| Cash Per Share | 0.19 X | |||
| Current Ratio | 16.25 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (3.3 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 10 | |||
| Beta | 0.61 | |||
| Market Capitalization | 35.82 M | |||
| Total Asset | 26.55 M | |||
| Net Asset | 26.55 M |
About Cynata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cynata Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cynata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cynata Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.